Most notably, there is emerging support for the use of neutrophil gelatinase‐associated lipocalin (NGAL), interleukin‐18 (IL‐18), liver‐type fatty acid‐binding protein (L‐FABP), and kidney injury molecule‐1 (KIM‐1) as AKI biomarkers. Here, LCN2 is linked to acute kidney injury.